Waldenström's macroglobulinemia epidemiology and demographics
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia epidemiology and demographics |
|
FDA on Waldenström's macroglobulinemia epidemiology and demographics |
|
CDC on Waldenström's macroglobulinemia epidemiology and demographics |
|
Waldenström's macroglobulinemia epidemiology and demographics in the news |
|
Blogs on Waldenström's macroglobulinemia epidemiology and demographics |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Mirdula Sharma, MBBS [3] Roukoz A. Karam, M.D.[4]
Overview
The prevalence of Waldenström macroglobulinemia is estimated to be 1,500 cases in United States annually. Waldenström's macroglobulinemia represents 1% of all hematological cancers.
Epidemiology and Demographics
- Lymphoplasmacytic lymphoma is one of the rare subtypes of NHL accounting just 1-2% of it.
Prevalence
- The prevalence of Waldenström macroglobulinemia is estimated to be 1,500 cases in United States annually.[1]
Incidence
- World-wide, age-adjusted incidence of Waldenström macroglobulinemia is 0.38 cases per 100,000 persons annually, increasing with age to 2.85 in patients above 80 years.[2]
Age
- The incidence of Waldenström's macroglobulinemia increases after 50 years of age.[3]
Gender
- Men are twice more likely than women to develop WM(5.4 vs. 2.7 per million, respectively). [1][4][5]
Race
References
- ↑ 1.0 1.1 1.2 1.3 Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R; et al. (2012). "Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study". Cancer. 118 (15): 3793–800. doi:10.1002/cncr.26627. PMID 22139816.
- ↑ Monge J, Braggio E, Ansell SM (2013). "Genetic factors and pathogenesis of Waldenström's macroglobulinemia". Curr Oncol Rep. 15 (5): 450–6. doi:10.1007/s11912-013-0331-7. PMC 3807757. PMID 23901022.
- ↑ Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015
- ↑ 4.0 4.1 4.2 Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L; et al. (2017). "Waldenström Macroglobulinemia: Review of Pathogenesis and Management". Clin Lymphoma Myeloma Leuk. 17 (5): 252–262. doi:10.1016/j.clml.2017.02.028. PMC 5413391. PMID 28366781.
- ↑ Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H; et al. (2007). "Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus". JAMA. 297 (18): 2010–7. doi:10.1001/jama.297.18.2010. PMID 17488966.
- ↑ Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006). "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001". Blood. 107 (1): 265–76. doi:10.1182/blood-2005-06-2508. PMC 1895348. PMID 16150940.